Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia

Sánchez-Quesada, José Luís; Otal-Entraigas, Carles; Franco, M.; Jorba, Oscar Jorba; González‐Sastre, Francesc; Blanco‐Vaca, Francisco; Ordóñez-Llanos, Jordi

doi:10.1016/s0002-9149(99)00411-7

Cited by 79 publications

(55 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Familial hypercholesterolemia and hypertriglyceridemia present a proportion of LDL(-) 3-5 fold higher than normolipemic healthy subjects Sanchez-Quesada, 1999). These results were obtained using ultracentrifugation plus anion-exchange chromatography, both being laborious and time-consuming techniques.…”

Section: Association Of Ldl(-) With Cardiovascular Riskmentioning

confidence: 95%

“…Statin therapy decreases the proportion of LDL(-) but the process is not parallel to the lipidlowering effect. This is because total LDL cholesterol decreases very rapidly (in 2 weeks) whereas LDL(-) decreases more slowly (in up to six months) (Sanchez-Quesada, 1999). This suggests that LDL(-) generation not only depends on lipid metabolism but also on other factors such as chronic inflammation.…”

Section: Association Of Ldl(-) With Cardiovascular Riskmentioning

confidence: 99%

See 1 more Smart Citation

Modified Forms of LDL in Plasma

Sánchez-Quesada¹,

Villegas²

2012

Atherogenesis

View full text Add to dashboard Cite

Section: Association Of Ldl(-) With Cardiovascular Riskmentioning

confidence: 95%

Section: Association Of Ldl(-) With Cardiovascular Riskmentioning

confidence: 99%

Modified Forms of LDL in Plasma

Sánchez-Quesada¹,

Villegas²

2012

Atherogenesis

View full text Add to dashboard Cite

“…Simvastatina migliora la vasodilatazione endotelio-mediata [29] e la disponibilità di monossido di azoto [30] contribuendo così a ripristinare la normale funzione endoteliale. Simvastatina esercita inoltre un'azione antiossidante sulle LDL [31] e un evidente effetto antinfiammatorio, rilevato misurando i livelli di proteina C reattiva ad alta sensibilità (CRP) che in corso di trattamento si riduce del 23% [32]. La riduzione è rapida avvenendo entro 2 settimane, ed è indipendente dalla riduzione del colesterolo [33].…”

Section: Effetti Pleiotropiciunclassified

“…Francesco Vittorio Costa (1) , Orietta Zaniolo (2) Farmeconomia e percorsi terapeutici 2007; 8 (1): [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] dal fungo Penicillum Citrinum, il primo inibitore dell'HMG-CoA reduttasi (compactina ML-236B). Infine, nel 1979, Hoffman e colleghi, nei laboratori della MS&D, isolarono da un ceppo del fungo Aspergillus Terreus, la prima statina d'impiego clinico: lovastatina.…”

unclassified

Simvastatin: between clinics and health economics

Costa

Zaniolo

2007

View full text Add to dashboard Cite

Statins reduce the incidence of cardiovascular events, one of the most important public health problems and among the main leading causes of death. Their use has been increasing in the last decade and today they represent the first drug class in terms of public expenditure. In view of the introduction of generic simvastatin in the Italian market, this paper outlines a pharmacological and economic profile of this compound. Despite two decades of life, simvastatin remains competitive with other HMG-CoA inhibitors, inducing a dose-dependent, up to 43% cLDL reduction. In clinical trials evaluating hard endpoints, simvastatin treatment achieved a strong reduction of cardiovascular events, revascularization procedures and mortality. Review of the main published pharmacoeconomic studies on simvastatin consistently indicated good cost/effectiveness ratios in most geographic contexts; convenience of this therapy increases along with baseline cardiovascular risk. Among available statins inducing equivalent cholesterol reductions, generic simvastatin has the lowest daily costs. Assuming stable market volume, an estimated cost saving for the Italian National Health Service of about 1 million Euro per year is expected from the introduction of the generic drug. Further cost savings may accrue for a potential switch from more expensive statins to simvastatin. Albeit individual responses to statins are unpredictable, the choice to start with lower cost molecules can limit initial drug investment and dampen the negative financial impact of treatment interruptions and switches.

show abstract

“…Simvastatin is highly effective in reducing total plasma cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), very-low-density lipoprotein cholesterol (VLDL-C) and increasing highdensity lipoprotein cholesterol (HDL-C) in heterozygous familial forms of hypercholesterolemia, and in mixed hyperlipidemia 2,3 .…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evidences for Simvastatin and Losartan Potassium Interaction and Its in Vivo Implications

Arayne

Sultana

Haroon

et al. 2009

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

In the present paper, we describe the in vitro availability of simvastatin, a potent HMG-CoA reductase inhibitor, in presence of losartan potassium, which is a non-peptide angiotensin II receptor antagonist. These studies were carried out at 37, 48 and 60°C in different pH environments simulating human body compartments. The reactions were studied by UV spectroscopy and the availability of both drugs in presence of each other was determined by deriving a simultaneous equation for two component system through modification of Beer`s law. The interactions were further characterized by IR and H 1 NMR spectroscopic techniques. It was observed that availability of simvastatin in presence of losartan at 37 ºC in simulated gastric juice, at pH 7.4 and pH 9.0 was blocked by losartan through the formation of a charge-transfer complex while the availability of losartan in turn was immensely increased. In pH 4.0 these effects were reversed, availability of simvastatin increased and the availability of losartan was depressed. Similar results were observed at higher temperatures.

show abstract

Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia

Cited by 79 publications

References 28 publications

Modified Forms of LDL in Plasma

Modified Forms of LDL in Plasma

Simvastatin: between clinics and health economics

In Vitro Evidences for Simvastatin and Losartan Potassium Interaction and Its in Vivo Implications

Contact Info

Product

Resources

About